Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators.
about
Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancerAntiestrogens: structure-activity relationships and use in breast cancer treatmentBazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease.Bis-arylidene oxindoles as anti-breast-cancer agents acting via the estrogen receptor.Ligand-free estrogen receptor activity complements IGF1R to induce the proliferation of the MCF-7 breast cancer cells.Ligands specify estrogen receptor alpha nuclear localization and degradationMinireview: Not picking pockets: nuclear receptor alternate-site modulators (NRAMs)Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs).The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs).Selectively targeting estrogen receptors for cancer treatment.Mechanisms of progesterone receptor inhibition of inflammatory responses in cellular models of breast cancer.Expression and molecular consequences of inhibition of estrogen receptors in granulosa cells of bovine folliclesEvaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader.The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasisInduced protein degradation: an emerging drug discovery paradigm.Estrogen receptor β ligands: recent advances and biomedical applications.The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacyEvolutionary origins of the estrogen signaling system: insights from amphioxusLong-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells.Rapid modulation of synaptogenesis and spinogenesis by 17β-estradiol in primary cortical neurons.A Screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERDs).The Effects of Estrogen Receptors' Antagonist on Brain Edema, Intracranial Pressure and Neurological Outcomes after Traumatic Brain Injury in Rat.Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer.Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.Expression of estrogenicity genes in a lineage cell culture model of human breast cancer progression.Full antagonism of the estrogen receptor without a prototypical ligand side chain.Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer.Androgen receptor antagonists: a patent review (2008-2011).Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome systemAdamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells.Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.The role of fulvestrant in endometrial cancer.Targeted Protein Degradation by Small Molecules.Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators.Targeted protein knockdown using small molecule degraders.Targeted Protein Degradation: from Chemical Biology to Drug Discovery.Erymildbraedin A and B, two novel cytotoxic dimethylpyrano-isoflavones from the stem bark of Erythrina mildbraedii: evaluation of their activity toward endocrine cancer cells.Endometrial Cancer-Associated FGF18 Expression Is Reduced by Bazedoxifene in Human Endometrial Stromal Cells In Vitro and in Murine Endometrium.Inhibitor mediated protein degradation.
P2860
Q26825584-B037A4AB-4509-4D03-820F-A1B11FF6C465Q28077245-5B7C07A0-2ACA-490D-97D8-8E5C26EED1CBQ30413295-50AB301D-AF06-48AA-AFFB-DFE15B293FBDQ30746277-786E5366-0049-4BD7-9E91-938D70611A77Q31073908-CBE1CEA0-FD40-4DC3-98EC-9E6B9516DAEEQ33767111-745E11D3-6C45-4914-91CF-137CE39F20F8Q33780204-34E18DFF-690A-4866-92BC-0A97DD730688Q34047079-FFEB5AE7-8402-4386-BE36-FE064D4717FDQ34311300-58CF7601-F394-4184-8CF3-2262AFD0BCBDQ34315413-E9213A30-4845-40C3-91A9-43BDD7099C88Q34349374-0AD7A534-C3F1-4251-8C56-6ECFD3830C25Q34392493-2080DC28-9301-4C23-93A0-B8DC265B84C4Q34410743-B640B12F-E3BA-4D51-BD46-C8F95112BC84Q34484414-7DC67020-AB89-452F-9406-32E5D71C16C9Q34485137-48912C53-3DF9-41FE-9583-B869F84B9EB2Q34545841-42F843B2-7AA2-4933-855C-69E5A043F387Q35016384-CF13303E-B0F4-4103-BFE3-14D128FC52C0Q35027844-835F03D9-3C12-4535-8CAE-4516412DC6F3Q35230768-3160ECFD-7B5A-4C43-AFE3-5E02DE5D9BDDQ35234377-FA1042D9-0B6C-4D8D-A26B-E5A16F66F44DQ35407526-39A670E3-5EB3-42C6-B4D5-0FB4268FF4DDQ35596991-1640FA3F-3D2F-46F4-9F5A-857833BEA8C5Q36062887-CC81DA31-1961-48E1-964D-956351F734EEQ36450456-BE6FE025-534D-4AD6-BBF8-7950568770EEQ37156496-6BB5B8CB-0FD6-46BB-A65B-5C1D12DC48F3Q37169705-700E2411-07CF-442D-81EB-2482A6E327ABQ37510434-29596269-85C4-4D9D-B03B-AD1B13CB89E2Q37594444-8FBB8A81-7DA5-49FE-AFBD-7CC99AA34F7AQ38009888-8E718DF3-378E-408D-840E-B17E113612C6Q38181445-46ED3B96-D097-448C-AAE9-E8C6D581377CQ38430208-60E7C743-C6D8-411E-8681-B91F781D82D6Q38719706-E6B4815F-7F9B-49BA-B6FD-633805DE9463Q38970776-A5C4F193-8671-4D48-8FD0-F51A231A8E1BQ38978952-A86D343E-5486-4CC3-8059-529D0A076731Q39022052-2B83814A-B12E-46AF-8805-D8F271E7DD47Q39367115-F7CF1855-0645-40C5-9F03-C37A001D4D26Q39396984-AA8E7352-907B-463D-ADAB-F1BD3B1F08E6Q39782115-66B9A46E-B0E9-4768-95DA-D72EF3102690Q41640781-ACF57C28-9402-4F11-97D6-EBE4E7109B35Q42178606-5AB116B1-A79D-4A1B-9DF8-A3C0D4A61782
P2860
Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Definition of functionally imp ...... ogen receptor down-regulators.
@en
type
label
Definition of functionally imp ...... ogen receptor down-regulators.
@en
prefLabel
Definition of functionally imp ...... ogen receptor down-regulators.
@en
P2093
P1433
P1476
Definition of functionally imp ...... ogen receptor down-regulators.
@en
P2093
Andrea Sherk
Bryan M Wittmann
Donald P McDonnell
P304
P356
10.1158/0008-5472.CAN-07-1590
P407
P577
2007-10-01T00:00:00Z